

In-Office Laboratory Testing Payment EFFECTIVE DATE January 1, 2021

This policy does not and is not intended to detail all covered benefits offered by Bright HealthCare. In addition to the information included in this policy, Bright HealthCare reserves the right to apply its other standard coding and claims adjustment methodology to claims submitted by providers pursuant to this policy, including, without limitation, changes required or contemplated by the unique benefit design; standards required by law, regulation, or accreditation; industry standard reimbursement guidelines; and Bright HealthCare's provider manual. Providers must submit claims accurately to Bright HealthCare and ensure that such claims are properly coded for the treatment provided.

DEFINITIONS

- 1. "Benefit Plan" means a plan of health care benefits issued or administered by Bright Health under which Members receive coverage for Covered Services.
- 2. "Commercial Benefit Plans" means benefit plans issued or administered by Bright Health that are designed for purchase by individuals or groups and are not intended for government health programs such as Medicare, Medicaid, or the Children's Health Insurance Program.
- **3.** "Covered Services" means medically necessary health care services and supplies for which a Member is entitled to coverage under a Benefit Plan.
- **4.** "CPT Codes" are used to describe tests, surgeries, evaluations, and any other medical procedure performed by a healthcare provider on a patient.
- **5.** "Individual and Family Plans ("IFP")" means individual and family plans offered as an Exchange Benefit Plans and Off-Exchange Benefit Plans
- **6.** "In-Office Laboratory" means a laboratory procedural/diagnostic testing lab services performed in a physician's office, on an outpatient basis, with an abbreviated menu of tests outlined in this Policy.
- 7. "Medicare Advantage (MA) Benefit Plans" means benefit plans issued or administered by Bright HealthCare pursuant to the MA program.
- **8.** "Medicare Advantage" (sometimes called Medicare Part C or MA) means a type of health insurance plan.
- **9.** "Medicare" means the United States federal government health insurance program that subsidizes healthcare services.
- **10. "Member"** means an individual who is enrolled in a Bright HealthCare plan and eligible to receive benefits for Covered Services under a Benefit Plan.
- **11. "Network Laboratory"** means a participating laboratory in plan's network of laboratories that has a participation agreement in effect (either directly or indirectly) with Bright Health.



- **12. "Medically Necessary/Medical Necessity"** means health care services or supplies needed to diagnose or treat an illness, injury, condition, disease or its symptoms and that meet accepted standards of medicine.
- **13. "Outpatient"** means a patient that receives medical treatment without being admitted to the hospital.
- 14. "Program Requirements" means Bright Health's policies and procedures, protocols, payment and coding rules, and administrative requirements that establish the rules for Medical Group and Network Providers to participate in Bright Health's network and carry out the terms of this Agreement, including without limitation rules related to claims submission, coding and billing, prior authorization, utilization review programs, referral to specialists, credentialing procedures, Bright Health's quality improvement and accreditation programs, and risk adjustment and claims reconciliation programs.
- 15. "Prior Authorization ("PA")" means a process through which the physician or other health care Provider is required to obtain advance approval from the plan that payment will made for a service or item furnished to a Member. Unless specified otherwise with respect to an item or service, the Member is not responsible for obtaining (prior) authorization.
- 16. "Provider" means any participating or non-participating medical group, individual physician, or other healthcare service provider who is engaged in the delivery of health care services in a State and is licensed or certified by the State to engage in that activity in the State; and any entity that is engaged in the delivery of health care services in a State and is licensed or certified to deliver those services if such licensing or certification is required by State law or regulation.
- **17.** "Physician Office Laboratory" means a physician office laboratory is a laboratory maintained by a physician or group of physicians for performing diagnostic tests in connection with the physician practice.
- 18. "Small Group Plans" means health insurance plans that are established under the ACA under which individuals obtain health insurance coverage (directly or through any arrangement) on behalf of themselves (and their dependents) through a group health plan maintained by a small employer that may be purchased through a broker directly or may be offered on the state or federal health insurance marketplaces. Group size is state-specific. Generally, a group requires under 50 full-time employees, except for a few states which require under 99 full-time employees.¹



PURPOSE

The goal of this policy is to provide Bright Health guidelines for payment of approved laboratory CPT codes, that are provided in an office setting. The provision of laboratory services payment at Bright Health is integral to providing quality clinical care for members. The use of "in-office" laboratory testing provides members with current, safe, accurate and affordable health care. Laboratory testing is completed for diagnostic purposes and to provide information for wellness initiatives when appropriate.

SCOPE

This policy and procedure apply to all Bright Health departments, staff, and delegates under contract with Bright Health to support Bright Health's Commercial Plans, Individual and Family Plans (IFP), Small Group Plans (SG), and Medicare Advantage Plans (MA). This policy further applies to Bright Health Group, Inc. and all its affiliates, Providers, all Benefit Plans, and Bright Health members. This policy is a part of Bright Health's Program Requirements.

Notwithstanding the foregoing, in the event that this policy conflicts with Centers for Medicare and Medicaid Services (CMS) Medicare Advantage Organization (MAO) guidance and requirements CMS/MAO guidelines will prevail for the Medicare Advantage Plans only.

Before applying this Policy, please refer to the Member Benefit Plan document and any federal or state mandates, if applicable. If there is a difference between this policy and the Member specific plan document, the Member benefit plan document will govern.

POLICY

Bright Health will consider reimbursement for certain laboratory services, on an outpatient basis, in a physician's office according to its reimbursement policies, PA rules, and benefit guidelines. All other laboratory testing outside of the in-office laboratory testing must be performed at a participating lab according to Bright Health policies. Participating labs are found in the Bright Health Provider Directory.² Bright Health requires that each laboratory be accredited and maintain accreditation prior to consideration of reimbursement by a CLIA approved agency. Bright Health may conduct inspections of laboratories certificate of accreditation to ensure compliance with the CLIA program requirements.³

Bright Health follows its policies and Medicare processing guidelines. Medicare makes payment on laboratory services according to assignment and a fee schedule. ⁴ In no event, will Bright Health's reimbursement rate exceed the Provider's contracted rate, 100% of the Original

² Bright Health Provider Directory https://brighthealthcare.com/search

³ https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA

⁴ Medicare Claims Processing Manual https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/clm104c16.pdf



Medicare fee-for-service allowable rate, or Bright Health's Out of Network Payment Policy⁵ for emergency and authorized services. Pathologist are excluded from this Policy.

PROCEDURES

- I. The "In-Office Laboratory Testing and Procedure List" is a comprehensive list of laboratory testing and procedure codes for which Bright Health will consider payment to Providers when the service is performed in the physician's office. Please refer to Appendix A. Appendix A does not apply to Medicare Advantage plans. Medicare Advantage claim processing and payments will be in accordance with the CMS guidelines.⁶
- II. Medicare covers in-office laboratory services when:
 - A. The treating participating physician or a qualified non-physician practitioner orders the services;
 - B. Services are medically necessary; and
 - C. Services meet all Clinical Laboratory Improvement Amendments (CLIA) regulations ⁷
- III. All other laboratory testing outside of the in-office laboratory testing must be performed at a Network laboratory according to Bright Health policies. Participating labs are found in the Bright Health Provider Directory.⁸
- IV. Laboratory services are subject to the terms, conditions, and limitations of the member's benefit structure.
- V. Bright Health Network or Reimbursement Policy Department is responsible for the maintenance, monitoring or implementation the policy.
- VI. Pathologist are excluded from this Policy.
- VII. This policy will not take effect until October 1, 2021, for participating Providers.

REFERENCES/CITATIONS

G.S. 58-3-255

EXHIBITS/ATTACHMENTS

APPENDIX A - In-Office Laboratory Testing and Procedures List

POLICY HISTORY

https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network MLN/MLNProducts/Downloads/CLIABrochure.pdf

⁵ NET-018 Out of Network Payment Policy

⁶ Medicare Claims Processing Manual (cms.gov) See Section 50.2 Paragraph 3

⁷ CLIA Program and Medicare Laboratory Services

⁸ Bright Health Provider Directory https://brighthealthcare.com/search



Initial Approval Date: June 16, 2021 Version 2, Approval Date: July 16, 2021 Version 3, Approval Date: October 28, 2021

Appendix A

| In-Office Laboratory Testing and Procedures List Prior Authorization Requirements must be satisfied | | |
|---|------------------------------|--|
| Code | Description | |
| 80305 | Drug test prsmv dir opt obs | |
| 80306 | Drug test prsmv instrmnt | |
| 81000 | Urinalysis nonauto w/scope | |
| 81001 | Urinalysis auto w/scope | |
| 81002 | Urinalysis nonauto w/o scope | |
| 81003 | Urinalysis auto w/o scope | |
| 81025 | Urine pregnancy test | |
| 82043 | Microalbumin quantitative | |
| 82044 | Microalbumin semiquant | |
| 82247 | Bilirubin total | |
| 82270 | Occult blood feces | |
| 82271 | Occult blood other sources | |
| 82272 | Occult bld feces 1-3 tests | |
| 82670 | Assay of estradiol | |
| 82803 | Blood gases any combination | |
| 82947 | Assay glucose blood quant | |
| 82948 | Reagent strip/blood glucose | |
| 82962 | Glucose blood test | |
| 83014 | H pylori drug admin | |
| 83036 | Glycosylated hemoglobin test | |
| 83037 | Glycosylated hb home device | |
| 83516 | Immunoassay nonantibody | |
| 83655 | Assay of lead | |
| 83861 | Microfluid analy tears | |
| 84443 | Assay thyroid stim hormone | |
| 84703 | Chorionic gonadotropin assay | |
| 85007 | BI smear w/diff wbc count | |
| 85014 | Hematocrit | |
| 85018 | Hemoglobin | |
| 85025 | Complete cbc w/auto diff wbc | |
| 85027 | Complete cbc automated | |



| 85060 | Blood smear interpretation |
|-------|------------------------------|
| 85610 | Prothrombin time |
| 85651 | Rbc sed rate nonautomated |
| 86140 | C-reactive protein |
| 86308 | Heterophile antibody screen |
| 86403 | Particle agglut antbdy scrn |
| 86485 | Skin Test Candida |
| 86486 | Skin Test Nos Antigen |
| 86510 | Histoplasmosis Skin Test |
| 86580 | Tb intradermal test |
| 86701 | Hiv-1antibody |
| 86702 | Hiv-2 Antibody |
| 86703 | Hiv-1/hiv-2 1 result antbdy |
| 87210 | Smear wet mount saline/ink |
| 87220 | Tissue exam for fungi |
| 87651 | Strep a dna amp probe |
| 87804 | Influenza assay w/optic |
| 87880 | Strep a assay w/optic |
| 88331 | Path consult intraop 1 bloc |
| 88332 | Path Consult Intraop Addl |
| 88738 | Hgb quant transcutaneous |
| 89060 | Exam Synovial Fluid Crystals |
| 89250 | Cultr Oocyte/Embryo <4 Days |
| 89254 | Oocyte Identification |
| 89255 | Prepare Embryo For Transfer |
| 89257 | Sperm Identification |
| 89260 | Sperm Isolation Simple |
| 89261 | Sperm Isolation Complex |
| 89264 | Identify Sperm Tissue |
| 89268 | Insemination Of Oocytes |
| 89272 | Extended Culture Of Oocytes |
| 89300 | Semen Analysis W/Huhner |
| 89310 | Semen Analysis W/Count |
| 89320 | Semen Anal Vol/Count/Mot |
| 89321 | Semen Anal Sperm Detection |
| 89322 | Semen Anal Strict Criteria |
| 89330 | Evaluation Cervical Mucus |
| 89352 | Thawing Cryopresrved Embryo |
| | |



COVID-19 Additions:

| U0001 2019-ncov diagnostic p U0002 Covid-19 lab test non-cdc U0003 Cov-19 amp prb hgh thruput U0004 Cov-19 test non-cdc hgh thru U0005 Infec agen detec ampli probe 0202U Nfct ds 22 trgt sars-cov-2 0223U Nfct ds 22 trgt sars-cov-2 0224U Antibody sars-cov-2 titer(s) 0225U Nfct ds dna&rna 21 sarscov2 0226U Svnt sarscov2 elisa plsm srm 0240U Nfct ds vir resp rna 3 trgt 0241U Nfct ds vir resp rna 4 trgt 86318 Ia infectious agent antibody 86328 Ia nfct ab sarscov2 covid19 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87637 Sarscov2 kinf a&b amp prb 87811 Sars-cov-2 covid19 w/optic | COVID-19 Additions | |
|--|--------------------|------------------------------|
| U0003 Cov-19 amp prb hgh thruput U0004 Cov-19 test non-cdc hgh thru U0005 Infec agen detec ampli probe 0202U Nfct ds 22 trgt sars-cov-2 0223U Nfct ds 22 trgt sars-cov-2 0224U Antibody sars-cov-2 titer(s) 0225U Nfct ds dna&rna 21 sarscov2 0226U Svnt sarscov2 elisa plsm srm 0240U Nfct ds vir resp rna 3 trgt 0241U Nfct ds vir resp rna 4 trgt 86318 Ia infectious agent antibody 86328 Ia nfct ab sarscov2 covid19 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87637 Sarscov2&inf a&b amp prb 87637 Sars-cov-2 covid19 w/optic | U0001 | 2019-ncov diagnostic p |
| U0004 Cov-19 test non-cdc hgh thru U0005 Infec agen detec ampli probe 0202U Nfct ds 22 trgt sars-cov-2 0223U Nfct ds 22 trgt sars-cov-2 0224U Antibody sars-cov-2 titer(s) 0225U Nfct ds dna&rna 21 sarscov2 0226U Svnt sarscov2 elisa plsm srm 0240U Nfct ds vir resp rna 3 trgt 0241U Nfct ds vir resp rna 4 trgt 86318 Ia infectious agent antibody 86328 Ia nfct ab sarscov2 covid19 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | U0002 | Covid-19 lab test non-cdc |
| U0005 Infec agen detec ampli probe 0202U Nfct ds 22 trgt sars-cov-2 0223U Nfct ds 22 trgt sars-cov-2 0224U Antibody sars-cov-2 titer(s) 0225U Nfct ds dna&rna 21 sarscov2 0226U Svnt sarscov2 elisa plsm srm 0240U Nfct ds vir resp rna 3 trgt 0241U Nfct ds vir resp rna 4 trgt 86318 Ia infectious agent antibody 86328 Ia nfct ab sarscov2 covid19 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87637 Sarscov2&inf a&b&rsv amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | U0003 | Cov-19 amp prb hgh thruput |
| 0202U Nfct ds 22 trgt sars-cov-2 0223U Nfct ds 22 trgt sars-cov-2 0224U Antibody sars-cov-2 titer(s) 0225U Nfct ds dna&rna 21 sarscov2 0226U Svnt sarscov2 elisa plsm srm 0240U Nfct ds vir resp rna 3 trgt 0241U Nfct ds vir resp rna 4 trgt 86318 Ia infectious agent antibody 86328 Ia nfct ab sarscov2 covid19 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | U0004 | Cov-19 test non-cdc hgh thru |
| 0223U Nfct ds 22 trgt sars-cov-2 0224U Antibody sars-cov-2 titer(s) 0225U Nfct ds dna&rna 21 sarscov2 0226U Svnt sarscov2 elisa plsm srm 0240U Nfct ds vir resp rna 3 trgt 0241U Nfct ds vir resp rna 4 trgt 86318 Ia infectious agent antibody 86328 Ia nfct ab sarscov2 covid19 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | U0005 | Infec agen detec ampli probe |
| O224U Antibody sars-cov-2 titer(s) O225U Nfct ds dna&rna 21 sarscov2 O226U Svnt sarscov2 elisa plsm srm O240U Nfct ds vir resp rna 3 trgt O241U Nfct ds vir resp rna 4 trgt 86318 Ia infectious agent antibody 86328 Ia nfct ab sarscov2 covid19 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 0202U | Nfct ds 22 trgt sars-cov-2 |
| 0225U Nfct ds dna&rna 21 sarscov2 0226U Svnt sarscov2 elisa plsm srm 0240U Nfct ds vir resp rna 3 trgt 0241U Nfct ds vir resp rna 4 trgt 86318 Ia infectious agent antibody 86328 Ia nfct ab sarscov2 covid19 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 0223U | Nfct ds 22 trgt sars-cov-2 |
| 0226U Svnt sarscov2 elisa plsm srm 0240U Nfct ds vir resp rna 3 trgt 0241U Nfct ds vir resp rna 4 trgt 86318 Ia infectious agent antibody 86328 Ia nfct ab sarscov2 covid19 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 0224U | Antibody sars-cov-2 titer(s) |
| 0240U Nfct ds vir resp rna 3 trgt 0241U Nfct ds vir resp rna 4 trgt 86318 Ia infectious agent antibody 86328 Ia nfct ab sarscov2 covid19 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 0225U | Nfct ds dna&rna 21 sarscov2 |
| 0241U Nfct ds vir resp rna 4 trgt 86318 Ia infectious agent antibody 86328 Ia nfct ab sarscov2 covid19 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 0226U | Svnt sarscov2 elisa plsm srm |
| 86318 la infectious agent antibody 86328 la nfct ab sarscov2 covid19 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 0240U | Nfct ds vir resp rna 3 trgt |
| 86328 Ia nfct ab sarscov2 covid19 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 0241U | Nfct ds vir resp rna 4 trgt |
| 86408 Neutrlzg antb sarscov2 scr 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 86318 | la infectious agent antibody |
| 86409 Neutrlzg antb sarscov2 titer 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 86328 | la nfct ab sarscov2 covid19 |
| 87635 Sars-cov-2 covid-19 amp prb 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 86408 | Neutrlzg antb sarscov2 scr |
| 86769 Sars-cov-2 covid-19 antibody 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 86409 | Neutrlzg antb sarscov2 titer |
| 87426 Sarscov coronavirus ag ia 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 87635 | Sars-cov-2 covid-19 amp prb |
| 87636 Sarscov2 & inf a&b amp prb 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 86769 | Sars-cov-2 covid-19 antibody |
| 87637 Sarscov2&inf a&b&rsv amp prb 87811 Sars-cov-2 covid19 w/optic | 87426 | Sarscov coronavirus ag ia |
| 87811 Sars-cov-2 covid19 w/optic | 87636 | Sarscov2 & inf a&b amp prb |
| Caro con E conta to imperio | 87637 | Sarscov2&inf a&b&rsv amp prb |
| | 87811 | Sars-cov-2 covid19 w/optic |
| 87428 Sarscov & inf vir a&b ag ia | 87428 | Sarscov & inf vir a&b ag ia |
| C9803 Hopd covid-19 spec collect | C9803 | Hopd covid-19 spec collect |
| G2023 Specimen collect covid-19 | G2023 | Specimen collect covid-19 |
| G2024 Spec coll snf/lab covid-19 | G2024 | Spec coll snf/lab covid-19 |